SARS-CoV-2 infection in two patients following recent lung transplantation
暂无分享,去创建一个
B. Sczepanski | M. Hecker | N. Kneidinger | R. Koczulla | S. Michel | I. Askevold | C. Schneider | S. Kuhnert | Adám Koteczki
[1] Antonio Romanelli,et al. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis , 2020, American Journal of Transplantation.
[2] Heng Lin,et al. COVID-19 in posttransplant patients—report of 2 cases , 2020, American Journal of Transplantation.
[3] Ke Ma,et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study , 2020, BMJ.
[4] M. Mehra,et al. COVID-19: Yet another coronavirus challenge in transplantation , 2020, The Journal of Heart and Lung Transplantation.
[5] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[6] Jiyuan Zhang,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.
[7] S. Lo,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.
[8] G. Gray,et al. A Mini-Review of Adverse Lung Transplant Outcomes Associated With Respiratory Viruses , 2019, Front. Immunol..
[9] A. von Brunn,et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 , 2012, Virus Research.
[10] F. Berthoux,et al. Impact of Mycophenolic Acid and Tacrolimus on Th17-Related Immune Response , 2011, Transplantation.